← Back

CryoCell International Inc

CCELUSD
4.36-1.4%1Y · USD

Cryo-Cell International, Inc. provides cord blood and cord tissue cryopreservation services in the United States. It offers cellular processing and cryogenic storage for family use, mainly for the collection and preservation of umbilical cord blood and tissue stem cells, as well as cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company also manufactures PrepaCyte CB processing system units for processing umbilical cord blood stem cells and provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents and through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Price · split & dividend adjusted
News & notes moving CCEL
United States
CCEL▲

CRYO-CELL International Q3 GAAP EPS of $0.16 Beats Estimates

CRYO-CELL International reported fiscal third-quarter 2026 GAAP earnings per share of $0.16, beating estimates by $0.13. Revenue came in at $7.82 million, down 0.1% year over year, but still ahead of expectations by $0.37 million. Shares of the cord blood banking company rose 4.56% following the release. The results were announced in a company press release.
CCEL · Capital · Positive Q3 GAAP EPS of $0.16 beat estimates by $0.13 and revenue topped expectations, driving shares up 4.56%.
Read original ↗
Seeking Alpha·1dRead more →